Category News

News

AndzonBio2, the ALBORADA Drug Discovery Institute at the University of Cambridge and Cambridge Enterprise Announce a Collaboration to Develop First-in-Class Therapeutics for Neuroinflammation

Paris, France and Cambridge, UK, May 13, 2026 – AndzonBio2 today announced the signature of agreements with the ALBORADA Drug Discovery Institute (ADDI) at the University of Cambridge and Cambridge Enterprise to advance a new class of therapeutics targeting neuroinflammation,…

andzonbi2
May 13, 2026

News

AndzonBio2 Strengthens Scientific and Strategic Capabilities with New Advisory Board and Leadership Appointment.

Paris, February 3, 2026 – AndzonBio2, a biotechnology company focused on developing innovative therapeutic programs in neuroinflammation, today announced the formation of its Scientific Advisory Board (SAB), comprised of leading experts in neuroscience, neurodegeneration, drug discovery, and translational development. The…

andzonbi2
February 3, 2026

News

AndzonBio2 emerges from stealth mode and announces initial €3M seed fundingto advance breakthrough treatments for neurological disorders.

Paris, France, October 23, 2025 – AndzonBio2 emerges from stealth mode and announces a €3M ($3.5M) seed funding from AdBio Partners, a venture capital company builder fund specialized in early-stage investments in life sciences, and Inserm Transfert, the private subsidiary…

andzonbi2
October 23, 2025